A PHASE I/II, MULTICENTER, OPEN-LABEL, NONCOMPARATIVE AIDS CLINCAL TRIALS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 在第一阶段，评估雷特格韦添加到初始稳定背景治疗中的短期安全性和耐受性，然后在年龄组为？的儿童和青少年中进行优化。<6个月，？2个月至<2年，？2至<12年，以及？12至<19岁。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In stage I, to evaluate the short term safety and tolerability of raltegravir added to an initial stable background therapy which will then be optimized in children and adolescents in the age groups of ???weeks to <6 months, ?? months to <2 years, ?2 to <12 years, and ?12 to <19 years.